Three trials with short-acting GLP-1RAs, exenatide and lixisenatide, showed slowed motor decline, though longer-acting formulations have not replicated this
Supplementary information Source data Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made
Whats Coming Orforglipron, Lillys oral GLP-1 (non-peptide), is in late-phase trials
GLP-1 (glucagon-like peptide-1) agonists have become a popular and effective option for weight loss, especially for individuals struggling with obesity or weight-related health issues
Others find that evening dosing helps control nighttime snacking, which is a significant calorie source for many people
This implies that, similar to other cardiovascular and metabolic treatments, people cannot discontinue the medication if they wish to maintain their weight loss
